At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AKTX Akari Therapeutics PLC
Market Closed 12-12 16:00:00 EST
0.3894
-0.0206
-5.02%
盘后0.3877
-0.0017-0.44%
18:32 EST
High0.4700Low0.3661Vol500.84K
Open0.4009D1 Closing0.4100Amplitude25.34%
Mkt Cap13.92MTradable Cap2.19MTotal Shares35.74M
T/O216.57KT/O Rate8.91%Tradable Shares5.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week
MT Newswires Live  ·  12-13 00:17
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
MT Newswires Live  ·  12-12 00:10
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
MT Newswires Live  ·  12-11
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
BRIEF-Akari Therapeutics Announces Preclinical Data On AKTX-101 For Pancreatic Cancer
Reuters  ·  12-09
BRIEF-Akari Therapeutics Announces Preclinical Data On AKTX-101 For Pancreatic Cancer
Akari Therapeutics Plc - Announces Preclinical Data on Aktx-101 for Pancreatic Cancer
THOMSON REUTERS  ·  12-09
Akari Therapeutics Plc - Announces Preclinical Data on Aktx-101 for Pancreatic Cancer
Akari Therapeutics Plc - Plans First-in-Human Trial for Aktx-101 in Late 2026
THOMSON REUTERS  ·  12-09
Akari Therapeutics Plc - Plans First-in-Human Trial for Aktx-101 in Late 2026
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
GlobeNewswire  ·  12-09
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
European Equities Traded in the US as ADRs Little Changed in Monday Trading
MT Newswires Live  ·  12-09
European Equities Traded in the US as ADRs Little Changed in Monday Trading
BRIEF-Akari Therapeutics Provides Corporate Update
Reuters  ·  12-04
BRIEF-Akari Therapeutics Provides Corporate Update
Press Release: Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
Dow Jones  ·  12-04
Press Release: Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
ADRs End Lower; Akari Therapeutics PLC Declines 17%
Dow Jones  ·  12-02
ADRs End Lower; Akari Therapeutics PLC Declines 17%
Akari Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance
Reuters  ·  11-27
Akari Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
MT Newswires Live  ·  11-27
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading
MT Newswires Live  ·  11-25
European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading
Analysts’ Top Healthcare Picks: Qiagen (QGEN), Akari Therapeutics (AKTX)
TIPRANKS  ·  11-20
Analysts’ Top Healthcare Picks: Qiagen (QGEN), Akari Therapeutics (AKTX)
BRIEF-Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag As Interim Chief Financial Officer
Reuters  ·  11-18
BRIEF-Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag As Interim Chief Financial Officer
Press Release: Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
Dow Jones  ·  11-18
Press Release: Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
European Equities Traded in the US as American Depositary Receipts Slightly Lower in Monday Trading
MT Newswires Live  ·  11-18
European Equities Traded in the US as American Depositary Receipts Slightly Lower in Monday Trading
European Equities Traded in the US as American Depositary Receipts Start Week Trending Higher in Monday Trading
MT Newswires Live  ·  11-11
European Equities Traded in the US as American Depositary Receipts Start Week Trending Higher in Monday Trading
Akari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1
Reuters  ·  11-10
Akari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1

Introduction

Company Name.
Akari Therapeutics PLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Issue price:
--